BioInvent International AB (publ) (BINV) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the BioInvent Q3 Report 2025 presentation. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now, I will hand the conference over to the speakers, CEO Martin Welshoff and CFO Stephan Erickson. Please go ahead. Yes, welcome everybody to our Q3 Report presentation. And as usual, Stefan and myself will go through what has happened during that time period. Stefan will cover the financials. I will do the rest. And without any further ado, I will start the presentation. Our forward-looking statement. And I would like to start with a quick summary. What has happened, events in the third quarter, as well as the events after the end of the period. And obviously one very important event during the third quarter was our prioritization in the portfolio to really focus on the two lead programs, all the resources doubling down on the two most advanced programs, 1808 and 1206. And I will come back to more details later. And then the other thing was that there was a change in the board. So Vincent Ossipo, who is with us for many, many, many years, stepped down for, you know, priority reasons. And I think this is a very normal change. And as I said, it has been with us almost 10 years. So then the events after the end of the period. So the most important thing, and we probably will discuss it also later a little bit more in detail. We are 12 for 6. We started the phase 2A trial. in advanced or metastatic non-small cell lung cancer and the real melanoma. And this is a first line study. So super exciting. So this is basically based on the good data that we have generated in heavily pre-treated patients. We showed that data to Merck and they agreed that we could go in the combo trial in first lin...